152 related articles for article (PubMed ID: 27801288)
1. The role of anaemia in oxidative and genotoxic damage in transfused β-thalassaemic patients.
Ferro E; Visalli G; La Rosa MA; Civa R; Papa GR; D'Ascola DG; Roccamo G; Piraino B; Salpietro C; Di Pietro A
Hematology; 2017 Apr; 22(3):183-191. PubMed ID: 27801288
[TBL] [Abstract][Full Text] [Related]
2. Genotoxic effect of iron overload and disease complications in transfused β thalassaemic patients.
Ferro E; Visalli G; La Rosa MA; Piraino B; Civa R; Randazzo Papa G; Di Pietro A
Mutagenesis; 2017 Mar; 32(2):275-281. PubMed ID: 27932515
[TBL] [Abstract][Full Text] [Related]
3. Oxidative damage and genotoxicity biomarkers in transfused and untransfused thalassemic subjects.
Ferro E; Visalli G; Civa R; La Rosa MA; Randazzo Papa G; Baluce B; D'Ascola DG; Piraino B; Salpietro C; Di Pietro A
Free Radic Biol Med; 2012 Nov; 53(10):1829-37. PubMed ID: 22995637
[TBL] [Abstract][Full Text] [Related]
4. Intracellular iron overload leading to DNA damage of lymphocytes and immune dysfunction in thalassemia major patients.
Shaw J; Chakraborty A; Nag A; Chattopadyay A; Dasgupta AK; Bhattacharyya M
Eur J Haematol; 2017 Nov; 99(5):399-408. PubMed ID: 28815805
[TBL] [Abstract][Full Text] [Related]
5. Effect of iron salts, haemosiderins, and chelating agents on the lymphocytes of a thalassaemia patient without chelation therapy as measured in the comet assay.
Anderson D; Yardley-Jones A; Vives-Bauza C; Chua-Anusorn W; Cole C; Webb J
Teratog Carcinog Mutagen; 2000; 20(5):251-64. PubMed ID: 10992272
[TBL] [Abstract][Full Text] [Related]
6. Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells.
Prus E; Fibach E
Acta Haematol; 2010; 123(1):14-20. PubMed ID: 19923794
[TBL] [Abstract][Full Text] [Related]
7. Role of non-invasive assessment in prediction of preclinical cardiac affection in multi-transfused thalassaemia major patients.
Said Othman KM; Elshazly SA; Heiba NM
Hematology; 2014 Oct; 19(7):380-7. PubMed ID: 24225039
[TBL] [Abstract][Full Text] [Related]
8. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
[TBL] [Abstract][Full Text] [Related]
9. Labile iron pool as a parameter to monitor iron overload and oxidative stress status in β-thalassemic erythrocytes.
Chutvanichkul B; Vattanaviboon P; Mas-Oodi S; U-Pratya Y; Wanachiwanawin W
Cytometry B Clin Cytom; 2018 Jul; 94(4):631-636. PubMed ID: 29486524
[TBL] [Abstract][Full Text] [Related]
10. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
Elalfy MS; Saber MM; Adly AA; Ismail EA; Tarif M; Ibrahim F; Elalfy OM
Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112
[TBL] [Abstract][Full Text] [Related]
11. N-Acetylcysteine supplementation reduces oxidative stress and DNA damage in children with β-thalassemia.
Ozdemir ZC; Koc A; Aycicek A; Kocyigit A
Hemoglobin; 2014; 38(5):359-64. PubMed ID: 25222041
[TBL] [Abstract][Full Text] [Related]
12. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
[TBL] [Abstract][Full Text] [Related]
13. Iron and oxidative stress in cardiomyopathy in thalassemia.
Berdoukas V; Coates TD; Cabantchik ZI
Free Radic Biol Med; 2015 Nov; 88(Pt A):3-9. PubMed ID: 26216855
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients.
Taher AT; Musallam KM; Wood JC; Cappellini MD
Am J Hematol; 2010 Apr; 85(4):288-90. PubMed ID: 20143405
[No Abstract] [Full Text] [Related]
15. Effects of iron salts and haemosiderin from a thalassaemia patient on oxygen radical damage as measured in the comet assay.
Anderson D; Yardley-Jones A; Hambly RJ; Vives-Bauza C; Smykatz-Kloss V; Chua-Anusorn W; Webb J
Teratog Carcinog Mutagen; 2000; 20(1):11-26. PubMed ID: 10607374
[TBL] [Abstract][Full Text] [Related]
16. Iron status and oxidative stress in beta-thalassemia patients in Jakarta.
Laksmitawati DR; Handayani S; Udyaningsih-Freisleben SK; Kurniati V; Adhiyanto C; Hidayat J; Kusnandar S; Dillon HS; Munthe BG; Wirawan R; Soegianto RR; Ramelan W; Freisleben HJ
Biofactors; 2003; 19(1-2):53-62. PubMed ID: 14757977
[TBL] [Abstract][Full Text] [Related]
17. DNA damage: beta zero versus beta plus thalassemia.
Sagar CS; Kumar R; Sharma DC; Kishor P
Ann Hum Biol; 2015; 42(6):585-8. PubMed ID: 25541274
[TBL] [Abstract][Full Text] [Related]
18. Extramedullary hematopoiesis is associated with lower cardiac iron loading in chronically transfused thalassemia patients.
Ricchi P; Meloni A; Spasiano A; Neri MG; Gamberini MR; Cuccia L; Caruso V; Gerardi C; D'Ascola DG; Rosso R; Campisi S; Rizzo M; Terrazzino F; Vangosa AB; Chiodi E; Missere M; Mangione M; Positano V; Pepe A
Am J Hematol; 2015 Nov; 90(11):1008-12. PubMed ID: 26228763
[TBL] [Abstract][Full Text] [Related]
19. Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age.
Berdoukas V; Nord A; Carson S; Puliyel M; Hofstra T; Wood J; Coates TD
Am J Hematol; 2013 Nov; 88(11):E283-5. PubMed ID: 23861216
[TBL] [Abstract][Full Text] [Related]
20. [Liver and heart iron deposition status in patients with β thalassemia major: a multicenter study].
Li C; Liu S; Wang Y; Wen F; Gao H; Chen G; Li C; Wu X; Fang J; Hao W; Liu R; Zhang X; Chu CW; Au W
Zhonghua Er Ke Za Zhi; 2014 Feb; 52(2):90-3. PubMed ID: 24739717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
